Waltham-based Thermo Fisher Scientific Inc., which has operations in Central Massachusetts, has established a specialty diagnostics segment following its recent acquisition of Phadia, a Swedish blood testing company.
Thermo Fisher said that the new financial reporting structure will provide investors with better visibility into its operations.
The specialty diagnostics segment, which drives more than $2 billion in revenues, will become the company’s third reporting segment. The others are analytical technologies and laboratory products and services.
